STVN | Ticker Profile - Titan Protect

STVN

Stevanato Group S.p.A.

Healthcare · Medical Instruments & Supplies · NYQ

$18.46

Data: 2026-05-28

✓ ETHICAL PASS

Unknown MOAT

HIGH

Data Confidence: 100.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$4.9B

Total market value of the company

Trailing P/E

30.63

Premium valuation

Forward P/E

21.26

Based on estimated future earnings — lower means cheaper

Rev Growth

+6.6%

Year-over-year revenue change

Profit Margin

11.7%

How much profit the company keeps from each dollar of revenue

ROE

9.6%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$25.00

+35% from current price — median analyst estimate

Recommendation

BUY

Consensus view from 9 analysts covering this stock

About Stevanato Group S.p.A.

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide solutions for biopharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. It operates through two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. The company offers drug containment solutions comprising pre-fillable syringes, cartridges, vials, and ampoules; in-vitro diagnostic solutions; drug delivery systems, including pen injectors, auto-injectors, and wearable injectors; diagnostic laboratory consumables; analytical and regulatory support services; medical devices; pharmaceutical visual inspection machines; assembling and packaging machines; glass converting machines; and after-sales services, such as line optimization and line conversions, training, logistics, spare parts and maintenance services. It also provides contract development and manufacturing services for customer-owned drug delivery devices. The company serves pharmaceutical, biotechnology, diagnostics, and life sciences companies; and drug products, glass packaging, and fill and finish contract manufacturers. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L.

https://www.stevanatogroup.com

Country: Italy Employees: 6,010 Industry: Medical Instruments & Supplies

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% PASS

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

ACCUMULATION

Smart money appears to be building positions quietly

Sharpe Ratio

0.231

Positive but modest risk-adjusted returns

Kelly Fraction

0.0060

Marginal edge — very small allocation suggested

Calmar Ratio

-0.020

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-1.0%

Historical annualised return based on price data

Max Drawdown

-52.0%

Largest peak-to-trough decline — the worst it has been

HMM State

BEAR

Statistical model detects bearish conditions

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

0.76

Less volatile than the market — more defensive

52W High

$28.00

34% below the year high

52W Low

$12.89

43% above the year low

Avg Volume

552,157

Average daily shares traded — higher means easier to buy and sell

Short Ratio

1.9

Days it would take all short sellers to cover — higher means more crowded

Short % Float

2.1%

Low short interest — limited bearish positioning

Div Yield

35.0%

Annual dividend as a percentage of the share price

EPS (TTM)

$0.59

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

29.43

Heavy leverage — higher financial risk if revenues decline

Current Ratio

1.63

Healthy liquidity position

Quick Ratio

1.11

Like current ratio but excludes inventory — stricter test

Gross Margin

29.2%

Revenue left after cost of goods — higher means pricing power

Operating Margin

14.2%

Profit from core operations before interest and tax

Free Cash Flow

$-57,059,124

Negative — the business is spending more than it generates

Revenue (TTM)

$1.2B

Total revenue over the last 12 months

Net Income

$141M

Profitable — the bottom line is positive

Analyst Coverage

Analysts

Target High

$32.00

Target Median

$25.00

Target Low

$17.50

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go